Fexuprazan (trade name Fexuclue) is a drug for the treatment of gastroesophageal reflux disease (GERD).[1] It is a potassium-competitive acid blocker.[2]

Fexuprazan
Clinical data
Trade namesFexuclue
Other namesAbeprazan; DWP14012; DWP-14012
ATC code
  • None
Legal status
Legal status
  • Rx in South Korea, Mexico
Identifiers
  • 1-[5-(2,4-Difluorophenyl)-1-(3-fluorophenyl)sulfonyl-4-methoxypyrrol-3-yl]-N-methylmethanamine
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC19H17F3N2O3S
Molar mass410.41 g·mol−1
3D model (JSmol)
  • CNCC1=CN(C(=C1OC)C2=C(C=C(C=C2)F)F)S(=O)(=O)C3=CC=CC(=C3)F
  • InChI=1S/C19H17F3N2O3S/c1-23-10-12-11-24(28(25,26)15-5-3-4-13(20)8-15)18(19(12)27-2)16-7-6-14(21)9-17(16)22/h3-9,11,23H,10H2,1-2H3
  • Key:OUNXGNDVWVPCOL-UHFFFAOYSA-N

Fexuprazan is approved for use in South Korea and Mexico.[3][4]

References

edit
  1. ^ Ramani A, Merchant A, Cash BD (August 2023). "Review of the clinical development of fexuprazan for gastroesophageal reflux-related disease". European Journal of Clinical Pharmacology. 79 (8): 1023–1029. doi:10.1007/s00228-023-03521-4. PMID 37344679. S2CID 259222741.
  2. ^ Kim GH, Choi MG, Kim JI, Lee ST, Chun HJ, Lee KL, et al. (November 2023). "Efficacy and Safety of Fexuprazan in Patients with Acute or Chronic Gastritis". Gut and Liver. 17 (6): 884–893. doi:10.5009/gnl220457. PMC 10651377. PMID 36789577.
  3. ^ "펙수클루정40밀리그램(펙수프라잔염산염)" [Fexuclue tablets 40 mg (fexuprazan hydrochloride)]. nedrug.mfds.go.kr (in Korean).
  4. ^ "Daewoong Pharma's GER drug gets product OK from Mexico". Korea Economic Daily. October 19, 2023.